
GSK, Pfizer resolve RSV patent feud amid vaccine market uncertainty
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory uncertainties, GSK and Pfizer have decided to lay to rest their patent feud. GSK and Pfizer have moved to scrap a patent lawsuit …